This time last year, following some spectacularly bad ‘web optimization’ work by pseudo-lawyer Marc Stephens, the Burzynski Clinic issued a press release. Marc’s misguided and heavy handed attempts to silence online criticism had resulted in the publication of over a hundred articles in six days.
The press release said that Marc’s actions were not appropriate and that he no longer had a professional relationship with the clinic. However, they maintained that UK bloggers had provided ‘inaccurate factual information’ and would be contacted by attorneys.
Since then I have been accused – usually on Twitter, by Burzynski supporters – of making things up, of lying and of defamation. And although I generally reply that I would be happy to correct anything inaccurate or misleading on my blog, I have never been shown a single sentence in need of editing.
I have never been contacted by anyone claiming to represent the clinic.
The press release listed some statements which the Burzynski Clinic claimed were false and defamatory.
There are no scientific studies supporting antineoplaston treatment since 2006. False – below is a list of publications and abstracts providing the results of FDA approved clinical trials since 2006 which demonstrate the treatment’s efficacy on a wide variety of brain tumors.
Have there actually been any scientific studies supporting antineoplaston treatment since 2006?
As far as I’m aware, Burzynski’s attorneys never did get round to contacting UK bloggers about this or indeed any ‘false and defamatory’ information on our blogs.
In fact, rather than threatening to sue any UK blogger who dares suggest otherwise, I’m not sure the Burzynski Clinic are actually allowed to claim efficacy for antineoplastons (including by press release). They are certainly not allowed to do so in a promotional context.
In October of this year, the FDA wrote to Dr Burzynski warning him that:
Antineoplastons are investigational new drugs that do not have marketing authorization in the
United States. An investigational new drug (IND) application was submitted to the FDA in [REDACTED]
Promotion of an investigational new drug is prohibited under FDA regulations at 21 CFR
312.7(a), which states, “A sponsor or investigator, or any person acting on behalf of a sponsor or investigator, or any person acting on behalf of a 1 sponsor or investigator, shall not represent in a promotional context that an investigational new drug is safe or effective for the purposes for which it is under investigation or otherwise promote the drug.”
Burzynski has been using these investigational ‘new’ drugs for over 35 years and in 1998 was ordered to cease and desist selling them outside of FDA supervised clinical trials. There are currently over 60 unfinished trials listed on clinicaltrials.gov.
Since we have never seen the publication of meaningful data from any of Burzynski’s numerous trials on antineoplastons, it would be impossible for anybody to objectively and truthfully claim that efficacy had been demonstrated. There are also well known side effects.